Why This Biotech Stock Lost Half Its Value In Just Three Days

Mirati Therapeutics' (MRTX) pain continued Thursday amid a series of analyst downgrades after MRTX stock lost about half of its value in three days.X Earlier this week, Mirati said 49% of patients with advanced lung cancer responded to a regimen using its drug, adagrasib, and Merck's…#fda #foodanddrugadministration #miratitherapeutics #berens #kras #citi #mirati #svbsecurities #merck #investorsbusinessdaily
Source: Reuters: Health - Category: Consumer Health News Source Type: news